<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">        <PMID Version="1">30293396</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0253-3766</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>40</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>23</Day>                    </PubDate>                </JournalIssue>                <Title>Zhonghua zhong liu za zhi [Chinese journal of oncology]</Title>                <ISOAbbreviation>Zhonghua Zhong Liu Za Zhi</ISOAbbreviation>            </Journal>            <ArticleTitle>[Oncological safety and prognosis factors analysis of immediate breast reconstruction after nipple-areola-complex sparing mastectomy].</ArticleTitle>            <Pagination>                <MedlinePgn>690-695</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0253-3766.2018.09.011</ELocationID>            <Abstract>                <AbstractText><b>Objective:</b> To explore the oncological safety of immediate breast reconstruction after nipple-areola complex(NAC) sparing mastectomy(NSM+ IBR) in patients with early stage breast cancer, and to analyze the prognostic factors of NSM+ IBR. <b>Methods:</b> From January 2004 to December 2015, the clinical data of 118 cases of stage Ⅰ-ⅡA breast cancer who had undergone NSM+ IBR in Tianjin Tumor Hospital were collected, comparing with 75 cases of Ⅰ-ⅡA breast cancer patients who had undergone immediate breast reconstruction after modified radical mastectomy (MRM+ IBR) at the same period. In addition to the prognosis of these two groups, the prognostic factors were also retrospectively analyzed. <b>Results:</b> The median follow-up were 53 months in the NSM+ IBR group and 51 months in the MRM+ IBR group, respectively. In the NSM+ IBR group, local recurrence, distant metastasis, death and NAC necrosis occurred in 4, 6, 9 and 4 cases during 3 years after operation, respectively. The local recurrence rate (LRR) was 3.4%, 3-year disease-free survival (DFS) rate was 91.5%, and the overall survival (OS) rate was 92.4%. In the MRM+ IBR group, local recurrence, distant metastasis, and death occurred in 1, 4, and 3 cases during 3 years after operation, respectively. The LRR was 1.3%, 3-year DFS was 93.3%, whereas the OS rate was 96.0%. No statistical difference was noted between the two groups (all <i>P</i>&gt;0.05). That HER-2 positive and molecular type correlated with the 3-year DFS (<i>P</i>&lt;0.05) independently and molecular type correlated with OS (<i>P</i>&lt;0.05) independently in the NSM+ IBR group. <b>Conclusions:</b> NSM does not impair patients' prognosis and could ensure oncological safety of patients with early stage breast cancer. IBR could improve female patients' figure and ensure the quality of life. HER-2 status and molecular type are the independent prognostic factors of the 3-year DFS. Molecular type is the independent prognosis factor of OS.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Z J</ForeName>                    <Initials>ZJ</Initials>                    <AffiliationInfo>                        <Affiliation>The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>W</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Z</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>X M</ForeName>                    <Initials>XM</Initials>                    <AffiliationInfo>                        <Affiliation>The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiao</LastName>                    <ForeName>C H</ForeName>                    <Initials>CH</Initials>                    <AffiliationInfo>                        <Affiliation>The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>chi</Language>            <PublicationTypeList>                <PublicationType UI="D003160">Comparative Study</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>China</Country>            <MedlineTA>Zhonghua Zhong Liu Za Zhi</MedlineTA>            <NlmUniqueID>7910681</NlmUniqueID>            <ISSNLinking>0253-3766</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016462" MajorTopicYN="N">Mammaplasty</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015411" MajorTopicYN="N">Mastectomy, Modified Radical</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015414" MajorTopicYN="Y">Mastectomy, Subcutaneous</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009558" MajorTopicYN="Y">Nipples</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D059351" MajorTopicYN="N">Organ Sparing Treatments</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <OtherAbstract Type="Publisher" Language="chi">            <AbstractText><b>目的：</b> 探讨保留乳头乳晕复合体(NAC)的乳腺癌改良根治术后即时重建(NSM＋IBR)的肿瘤学安全性，并分析影响NSM＋IBR预后的因素。 <b>方法：</b> 收集天津市肿瘤医院2004年1月至2015年12月的118例行NSM＋IBR的Ⅰ～ⅡA期乳腺癌患者资料，以同期收治的75例行未保留NAC的乳腺癌改良根治术后即时重建(MRM＋IBR)的Ⅰ～ⅡA期患者作为对照，回顾性分析两组患者的预后，并分析影响NSM＋IBR组患者预后的因素。 <b>结果：</b> NSM＋IBR组患者的中位随访时间为53个月，术后3年内远处转移6例，局部复发4例，NAC脱落4例，死亡9例，3年局部复发率(LRR)为3.4%，3年无病生存率为91.5%，3年总生存率为92.4%。MRM＋IBR组患者的中位随访时间为51个月，术后3年内远处转移4例，局部复发1例，死亡3例，3年LRR为1.3%，3年无病生存率为93.3%，3年总生存率为96.0%。两组患者的3年LRR、3年无病生存率和3年总生存率差异无统计学意义(均<i>P</i>&gt;0.05)。人表皮生长因子受体2(HER－2)状态和分子分型是影响NSM＋IBR患者无病生存的独立因素(均<i>P</i>&lt;0.05)，分子分型是影响NSM＋IBR患者总生存的独立因素(<i>P</i>&lt;0.05)。 <b>结论：</b> NSM＋IBR不会影响早期乳腺癌患者的预后，且可以保证肿瘤学安全性，维持女性患者的形象，提高生活质量。HER－2状态和分子分型是影响NSM＋IBR患者无病生存的独立因素，分子分型是影响NSM＋IBR患者总生存的独立因素。.</AbstractText>        </OtherAbstract>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Immediate breast reconstruction</Keyword>            <Keyword MajorTopicYN="N">Nipple-areola complex</Keyword>            <Keyword MajorTopicYN="N">Oncological safety</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30293396</ArticleId>            <ArticleId IdType="doi">10.3760/cma.j.issn.0253-3766.2018.09.011</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>